Replimune Group (REPL) Competitors $12.49 +0.48 (+4.00%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends REPL vs. JANX, EWTX, XENE, MRUS, TWST, ACAD, VCEL, MOR, SWTX, and KYMRShould you be buying Replimune Group stock or one of its competitors? The main competitors of Replimune Group include Janux Therapeutics (JANX), Edgewise Therapeutics (EWTX), Xenon Pharmaceuticals (XENE), Merus (MRUS), Twist Bioscience (TWST), ACADIA Pharmaceuticals (ACAD), Vericel (VCEL), MorphoSys (MOR), SpringWorks Therapeutics (SWTX), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry. Replimune Group vs. Janux Therapeutics Edgewise Therapeutics Xenon Pharmaceuticals Merus Twist Bioscience ACADIA Pharmaceuticals Vericel MorphoSys SpringWorks Therapeutics Kymera Therapeutics Replimune Group (NASDAQ:REPL) and Janux Therapeutics (NASDAQ:JANX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, community ranking, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability. Does the media prefer REPL or JANX? In the previous week, Replimune Group had 1 more articles in the media than Janux Therapeutics. MarketBeat recorded 6 mentions for Replimune Group and 5 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.23 beat Replimune Group's score of 0.83 indicating that Janux Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Janux Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, REPL or JANX? Janux Therapeutics has higher revenue and earnings than Replimune Group. Janux Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReplimune GroupN/AN/A-$215.79M-$3.05-4.10Janux Therapeutics$13.05M228.57-$58.29M-$1.17-48.57 Is REPL or JANX more profitable? Replimune Group has a net margin of 0.00% compared to Janux Therapeutics' net margin of -463.91%. Janux Therapeutics' return on equity of -10.47% beat Replimune Group's return on equity.Company Net Margins Return on Equity Return on Assets Replimune GroupN/A -53.12% -41.49% Janux Therapeutics -463.91%-10.47%-9.86% Do insiders and institutionals hold more shares of REPL or JANX? 92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are owned by institutional investors. 8.8% of Replimune Group shares are owned by insiders. Comparatively, 29.4% of Janux Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more risk & volatility, REPL or JANX? Replimune Group has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 3.29, suggesting that its share price is 229% more volatile than the S&P 500. Does the MarketBeat Community prefer REPL or JANX? Replimune Group received 125 more outperform votes than Janux Therapeutics when rated by MarketBeat users. However, 70.18% of users gave Janux Therapeutics an outperform vote while only 63.46% of users gave Replimune Group an outperform vote. CompanyUnderperformOutperformReplimune GroupOutperform Votes16563.46% Underperform Votes9536.54% Janux TherapeuticsOutperform Votes4070.18% Underperform Votes1729.82% Do analysts rate REPL or JANX? Replimune Group currently has a consensus target price of $17.29, suggesting a potential upside of 38.40%. Janux Therapeutics has a consensus target price of $89.90, suggesting a potential upside of 58.19%. Given Janux Therapeutics' higher probable upside, analysts clearly believe Janux Therapeutics is more favorable than Replimune Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Replimune Group 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Janux Therapeutics 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryJanux Therapeutics beats Replimune Group on 11 of the 17 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Replimune Group News Delivered to You Automatically Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REPL vs. The Competition Export to ExcelMetricReplimune GroupBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$821.69M$2.94B$5.13B$9.08BDividend YieldN/A1.90%4.93%4.22%P/E Ratio-4.1046.7389.5817.18Price / SalesN/A412.591,115.01116.87Price / CashN/A182.1042.8237.86Price / Book2.053.894.804.78Net Income-$215.79M-$42.21M$120.04M$225.60M7 Day Performance-0.48%-2.15%-1.91%-1.23%1 Month Performance13.03%4.20%11.48%3.36%1 Year Performance62.21%18.39%30.59%16.59% Replimune Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REPLReplimune Group4.5424 of 5 stars$12.49+4.0%$17.29+38.4%+67.4%$821.69MN/A-4.10210Insider TradeHigh Trading VolumeJANXJanux Therapeutics3.6708 of 5 stars$62.39+2.1%$89.90+44.1%+496.3%$3.27B$13.05M-52.2330Positive NewsEWTXEdgewise Therapeutics2.7263 of 5 stars$34.58+25.2%$42.33+22.4%+261.7%$3.27BN/A-22.8560Analyst ForecastAnalyst RevisionHigh Trading VolumeXENEXenon Pharmaceuticals2.7945 of 5 stars$40.96+2.3%$56.90+38.9%-5.8%$3.12B$9.43M-14.20251Insider TradeMRUSMerus2.8078 of 5 stars$42.78-0.1%$85.64+100.2%+61.7%$2.93B$43.95M-10.8437TWSTTwist Bioscience2.5561 of 5 stars$48.86+2.9%$51.90+6.2%+36.7%$2.90B$312.97M-13.19990ACADACADIA Pharmaceuticals3.8468 of 5 stars$17.35+0.5%$25.60+47.6%-41.9%$2.89B$726.44M22.13510VCELVericel1.4381 of 5 stars$57.97+0.9%$59.71+3.0%+66.0%$2.86B$226.84M957.83300Analyst ForecastMORMorphoSys0.127 of 5 stars$18.96+2.4%$14.33-24.4%N/A$2.86B$238.28M-5.45730News CoverageSWTXSpringWorks Therapeutics2.0114 of 5 stars$38.16-0.4%$69.50+82.1%+11.3%$2.84B$5.45M-9.87305KYMRKymera Therapeutics2.27 of 5 stars$43.73+3.8%$53.88+23.2%+66.0%$2.83B$87.56M-18.00170 Related Companies and Tools Related Companies Janux Therapeutics Alternatives Edgewise Therapeutics Alternatives Xenon Pharmaceuticals Alternatives Merus Alternatives Twist Bioscience Alternatives ACADIA Pharmaceuticals Alternatives Vericel Alternatives MorphoSys Alternatives SpringWorks Therapeutics Alternatives Kymera Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:REPL) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
